Skip to main content

Advertisement

Table 1 Baseline data of postmenopausal women with rheumatoid arthritis in the hormone replacement therapy (HRT) group and the control group

From: Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1

Characteristic HRT group Control group
Age (years) 57.0 ± 0.9 (41) 58.1 ± 0.7 (47)
Disease duration (years) 16.4 ± 1.9 (41) 15.5 ± 1.7 (47)
Years after menopause 8.4 ± 1.0 (36) 8.3 ± 0.8 (42)
Disease-modifying antirheumatic drugs 83% (41) 79% (47)
Glucocorticosteroid treatment 24% (41) 19% (47)
Nonsteroidal anti-inflammatory drugs 78% (41) 77% (47)
Positive serum test for rheumatoid factor 83% (40) 85% (47)
Serum TNF-α (pg/ml) 4.0 ± 0.4 (39) 4.4 ± 0.5 (46)
Serum IL-1Ra (pg/ml) 608 ± 123 (40) 485 ± 74 (47)
Serum IL-6 (pg/ml) 23.8 ± 5.7 (40) 22.4 ± 4.1 (47)
Serum sIL-6R (pg/ml) 822 ± 42 (39) 762 ± 31 (47)
Serum OPG (pg/ml) 113 ± 18 (37) 112 ± 12.8 (46)
Serum IGF-1 (ng/ml) 81.7 ± 4.4 (34) 78.2 ± 5.0 (43)
ESR (mm) 30.8 ± 3.0 (41) 26.5 ± 2.2 (46)
Serum estradiol (pmol/l) 47.7 ± 8.6 (31) 37.2 ± 4.0 (40)
  1. Values not shown as percentages are means ± standard error of the mean. Numbers of patients for whom data were available are shown in parentheses. ESR = erythrocyte sedimentation rate; IGF-1 = insulin-like growth factor 1; IL-1Ra = IL-1-receptor antagonist; OPG = osteoprotegerin; sIL-6R = soluble IL-6 receptor; TNF-α = tumor necrosis factor α.